- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.10. | bonyf AG receives the EU-MDR Certification Class IIa for PerioCream | 370 | Dow Jones News | DJ bonyf AG receives the EU-MDR Certification Class IIa for PerioCream
bonyf NV / Key word(s): Product Launch/Incoming Orders
bonyf AG receives the EU-MDR Certification Class IIa for PerioCream... ► Artikel lesen | |
| 15.09. | bonyf NV Showcases Innovative Product Portfolio at ExpoPharm 2025 in Düsseldorf | 355 | Dow Jones News | DJ bonyf NV Showcases Innovative Product Portfolio at ExpoPharm 2025 in Düsseldorf
bonyf NV / Key word(s): Conference/Corporate Action
bonyf NV Showcases Innovative Product Portfolio at ExpoPharm... ► Artikel lesen | |
| 05.09. | bonyf NV Cancels Planned Capital Increase Following Positive Strategic Developments | 278 | Dow Jones News | DJ bonyf NV Cancels Planned Capital Increase Following Positive Strategic Developments
bonyf NV / Key word(s): Financing/Corporate Action
bonyf NV Cancels Planned Capital Increase Following Positive... ► Artikel lesen | |
| BONYF Aktie jetzt für 0€ handeln | |||||
| 11.08. | Periocream: The Future Commercial Winner for bonyf | 365 | Dow Jones News | DJ Periocream: The Future Commercial Winner for bonyf
bonyf NV / Key word(s): Market Launch/Development of Sales
Periocream: The Future Commercial Winner for bonyf
11-Aug-2025 / 15:16 CET/CEST... ► Artikel lesen | |
| 14.07. | bonyf Reaffirms Its Long-Term Vision Amid Short-Term Market Volatility | 355 | Dow Jones News | DJ bonyf Reaffirms Its Long-Term Vision Amid Short-Term Market Volatility
bonyf NV / Key word(s): Corporate Action/Results Forecast
bonyf Reaffirms Its Long-Term Vision Amid Short-Term Market Volatility... ► Artikel lesen | |
| 30.06. | bonyf NV: Annual Results 2024 | 594 | Dow Jones News | DJ Annual Results 2024
bonyf NV / Key word(s): Annual Results/Financing
Annual Results 2024
30-Jun-2025 / 21:18 CET/CEST
=----------------------------------------------------------------------------------------------------------------------... ► Artikel lesen | |
| 03.06. | bonyf Welcomes Group Pharmaceuticals as Strategic Stakeholder to Drive Growth in India | 414 | Dow Jones News | DJ bonyf Welcomes Group Pharmaceuticals as Strategic Stakeholder to Drive Growth in India
bonyf NV / Key word(s): Capital Increase/Expansion
bonyf Welcomes Group Pharmaceuticals as Strategic Stakeholder... ► Artikel lesen | |
| 15.05. | bonyf NV Announces First Exports to the United States with Honest Pharma, Marking a Key Milestone in USA Growth Strategy | 569 | Dow Jones News | DJ bonyf NV Announces First Exports to the United States with Honest Pharma, Marking a Key Milestone in USA Growth Strategy
bonyf NV / Key word(s): Expansion/Market Launch
bonyf NV Announces First... ► Artikel lesen | |
| 08.04. | bonyf Advances to Phase 3 in the Development of Alginate-Organic Denture Fixative Cream | 360 | Dow Jones News | DJ bonyf Advances to Phase 3 in the Development of Alginate-Organic Denture Fixative Cream
bonyf NV / Key word(s): Research Update/Product Launch
bonyf Advances to Phase 3 in the Development of... ► Artikel lesen | |
| 13.03. | bonyf recently secures its EU Patent, US patent pending, for PerioTabs® & PerioCream, launch in March 2025 at the IDS Cologne | 472 | Dow Jones News | DJ bonyf recently secures its EU Patent, US patent pending, for PerioTabs® & PerioCream, launch in March 2025 at the IDS Cologne
bonyf NV / Key word(s): Product Launch/Patent
bonyf recently secures... ► Artikel lesen | |
| 18.02. | bonyf Announces Plans for Dual Listing on Nasdaq and Euronext Paris with a Five-Step Strategy | 431 | Dow Jones News | DJ bonyf Announces Plans for Dual Listing on Nasdaq and Euronext Paris with a Five-Step Strategy
bonyf NV / Key word(s): Corporate Action/Funds
bonyf Announces Plans for Dual Listing on Nasdaq... ► Artikel lesen | |
| 30.01. | bonyf R&D presents its two latest innovations at IDS 2025 in Cologne | 968 | Dow Jones News | DJ bonyf R&D presents its two latest innovations at IDS 2025 in Cologne
bonyf NV / Key word(s): Product Launch/Market Launch
bonyf R&D presents its two latest innovations at IDS 2025 in Cologne... ► Artikel lesen | |
| 10.12.24 | bonyf and Honest Pharma are pleased to announce a Strategic Alliance to bring revolutionary oral care products to the US market | 445 | Dow Jones News | DJ bonyf and Honest Pharma are pleased to announce a Strategic Alliance to bring revolutionary oral care products to the US market
bonyf NV / Key word(s): Alliance/Investment
bonyf and Honest Pharma... ► Artikel lesen | |
| 09.12.24 | bonyf Achieves MDR Certification, Strengthening Commitment to Excellence in Oral Care Solutions | 545 | Dow Jones News | DJ bonyf Achieves MDR Certification, Strengthening Commitment to Excellence in Oral Care Solutions
bonyf NV / Key word(s): Regulatory Admission/Regulatory Approval
bonyf Achieves MDR Certification... ► Artikel lesen | |
| 28.11.24 | bonyf expands its global formulation footprint through a strategic alliance with Group Pharmaceuticals Ltd, signing a license agreement to produce NitrAdine® for India | 446 | Dow Jones News | DJ bonyf expands its global formulation footprint through a strategic alliance with Group Pharmaceuticals Ltd, signing a license agreement to produce NitrAdine® for India
bonyf NV / Key word(s):... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 49,550 | -0,94 % | DEUTSCHE BANK RESEARCH stuft Fresenius SE auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Fresenius von 52 auf 53 Euro angehoben und die Einstufung auf "Buy" belassen. Die anstehenden Quartalszahlen des Medizinkonzerns... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 48,760 | +0,39 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 16,870 | 0,00 % | Alignment Healthcare Reports Third Quarter 2025 Results, Surpasses High-End of Guidance Across All Key Metrics | Reports Q3 revenue of $993.7 million, up 43.5% year-over-yearBeats high end of third quarter guidance and raises full-year outlook across all key metrics: membership, revenue, adjusted gross profit... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 46,460 | -0,21 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 33,040 | 0,00 % | BrightSpring Health Services GAAP EPS of $0.17 misses by $0.15, revenue of $3.33B misses by $20M | ||
| GERRESHEIMER | 27,340 | -0,94 % | Gerresheimer: Weitere Details - millionenschwere Fehlbuchung | Am Wochenende hat der Spezialverpackungshersteller Gerresheimer per Ad-Hoc-Mitteilung dem Kapitalmarkt weitere Details zur laufenden Prüfung problematischer Buchungen im Konzernbericht für das Fiskaljahr... ► Artikel lesen | |
| UNITEDHEALTH | 294,90 | +0,24 % | Earnings Preview - Teil 1: Make or Break für den Markt: Die Zahlen von UnitedHealth, Microsoft & Alphabet! | © Foto: Richard Drew/AP/dpaDiese in den kommenden Tagen (KW44) anstehenden US-Quartalszahlen müssen Anlegerinnen und Anleger kennen: Herausforderungen, Erwartungen und die aktuell eingepreisten Kursreaktionen... ► Artikel lesen | |
| GENEDX | 137,17 | +4,20 % | GeneDx raises 2025 revenue guidance to $428M amid accelerating exome and genome test growth | ||
| CARL ZEISS MEDITEC | 44,100 | +0,46 % | JPMORGAN stuft CARL ZEISS MEDITEC AG auf 'Underweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat Carl Zeiss Meditec mit einem Kursziel von 35,10 Euro auf "Underweight" belassen. Vor den am 11. Dezember anstehenden Quartalszahlen lägen seine... ► Artikel lesen | |
| BUTTERFLY NETWORK | 2,695 | 0,00 % | Butterfly Network reaffirms $91M-$95M 2025 revenue target while accelerating AI and chip innovation | ||
| PROCEPT BIOROBOTICS | 34,040 | 0,00 % | PROCEPT BioRobotics Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance | SAN JOSE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| HIMS & HERS HEALTH | 40,650 | +2,68 % | Gesundheit als Milliardenmarkt: PanGenomic Health, Hims & Hers, WW International | Immer mehr Menschen kümmern sich proaktiv um ihre Gesundheit - Vorsorge und Selbstfürsorge liegen im Trend. Laut aktuellen Studien von McKinsey ist die globale Wellness-Branche inzwischen rund 2 Billionen... ► Artikel lesen | |
| BETA BIONICS | 27,210 | 0,00 % | Beta Bionics, Inc.: Beta Bionics Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Guidance | IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial... ► Artikel lesen | |
| PROGYNY | 18,690 | 0,00 % | Progyny, Inc.: Progyny Expands Global Benefits to Include Pregnancy, Postpartum, and Menopause | Global employers can now empower their workforces with comprehensive women's health benefits, supported by localized expertiseNEW YORK, Oct. 22, 2025. (Nasdaq: PGNY), a global leader in women's health... ► Artikel lesen | |
| CLEARPOINT NEURO | 23,230 | 0,00 % | ClearPoint Neuro, Inc.: ClearPoint Neuro Announces Promising Results from Brain Tumor Laser Therapy Study to be Presented at the CNS Annual Meeting in Los Angeles | SOLANA BEACH, CALIFORNIA / ACCESS Newswire / October 7, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation... ► Artikel lesen |
Das Unternehmen BONYF NV kann der Branche Gesundheitswesen zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BONYF NV finden Sie auf Wallstreet Online.